Updates Center

• 
  AI-Powered Antibody Discovery: AtaGenix Leverages Cutting-Edge Technology to Slash Development Timelines

  On October 14, 2025, the biopharmaceutical industry is being reshaped by AI-driven antibody design, slashing development timelines from months to weeks with up to 100-fold efficiency gains. AtaGenix Laboratories leverages DeepMind’s AlphaFold to tackle complex CDR regions, generating high-affinity antibodies (Kd < 1 nM) for targets like GPCR and PD-L1. By integrating AI with robust wet-lab validation, including phage display and single B-cell cloning, AtaGenix mitigates data scarcity issues and reduces costs to <5% of traditional methods. Emerging tools like Chai-2 further highlight the field’s potential, achieving zero-shot de novo design with 16-20% hit rates. AtaGenix’s approach empowers clients to shift focus from discovery to clinical execution, redefining drug discovery economics.
• 
  AbbVie and RemeGen Partner on Novel PD-1/VEGF Bispecific Antibody

  AbbVie and RemeGen have announced an exclusive licensing agreement to co-develop RC148, a novel PD-1/VEGF bispecific antibody with strong potential in advanced solid tumors such as NSCLC and CRC. This multi-billion-dollar deal highlights the explosive growth of bispecific antibodies in oncology immunotherapy, particularly when combined with ADCs. The article also provides market snapshots showing rapid growth in bispecific, ADC, and custom antibody markets, with AtaGenix positioned as a comprehensive service provider supporting these innovations.
• 
  Antibody Discovery Paradigm Shift: Single B-Cell Cloning Challenges Phage Display Dominance

  single B-cell cloning, phage display, antibody discovery, native VH VL pairing, antibody development trends, hybridoma sequencing, nanobody, multispecific antibody, AtaGenix
• 
  First Commercial Bispecific ADC Projected by 2029 — Pipeline Tops 100 Clinical Candidates

  bispecific ADC, BsADC, antibody-drug conjugate, bispecific antibody, multispecific biologics, oncology pipeline, ADC linker payload, site-specific conjugation, China biopharma, AtaGenix
• 
  Global Antibody Discovery Market to Soar from USD 1.9B in 2024 to USD 3.3B by 2030

  The global antibody discovery market, valued at USD 1.9 billion in 2024, is projected to reach USD 3.3 billion by 2030, with a CAGR of 9.8%. Growth is fueled by expanding pipelines in monoclonal antibodies, rapid adoption of bispecifics, and increasing investment in antibody–drug conjugates (ADCs). Advances in single B-cell technologies, AI-driven design, and stable cell line development are accelerating discovery and reducing development risks. As demand rises for next-generation biologics, AtaGenix provides integrated discovery, screening, and engineering platforms to help researchers and partners achieve faster, cost-effective progress.